Loading…
Chinese biotech developing targeted small-molecule oncology drugs, including EGFR-mutant lung-cancer therapies.
Chinese biotech developing targeted small-molecule oncology drugs, including EGFR-mutant lung-cancer therapies.
Has moved from research to selling: its lead EGFR exon20 lung-cancer drug, sunvozertinib, is approved in China, so income now begins with drug sales to hospitals, topped up by licensing payments and investor funding for the rest of the pipeline. It trades on Shanghai's STAR board for science and technology companies.
In one line: A China-based clinical-stage oncology biotech.
Moat: narrow (IP / patents). Patent-protected, clinically differentiated targeted-oncology pipeline.
Headquarters: Shanghai, China · Employees: 1,009
Size Dizal Pharmaceutical (688192.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $4.68B, the 546th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥67.12 on 6 Nov 2026.
Performance Over six months the shares gained 18.4%, against +9.2% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 720.1% over the last twelve months (peer median +6.3%); the operating margin is 69.0% (peer median 11.0%).
Valuation It trades at 9.5× forward earnings against a peer median of 14.7× (4th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +96%, so the hurdle is -104 pp: the price already allows for a slowdown.
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.98B | CN¥801M | CN¥359M | CN¥90.9M | CN¥0 |
| Revenue growth | — | +123% | +295% | — | — |
| Gross profit | CN¥4.94B | CN¥691M | CN¥273M | CN¥15.0M | -CN¥63.1M |
| EBITDA | n/a | -CN¥745M | -CN¥897M | -CN¥1.08B | -CN¥730M |
| Net income | CN¥3.45B | -CN¥764M | -CN¥846M | -CN¥1.11B | -CN¥736M |
| Free cash flow | CN¥3.41B | -CN¥759M | -CN¥788M | -CN¥1.00B | -CN¥677M |
| Capital expenditure | CN¥70.2M | CN¥170M | CN¥138M | CN¥32.1M | CN¥73.8M |
| Total debt | CN¥1.29B | CN¥1.24B | CN¥1.16B | CN¥410M | CN¥85.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dizal Pharmaceutical 688192.SS | $4.68B | +18% | +720% | 69% | 9.5× | -8.4% |
| Shanghai Allist Pharmaceuticals 688578.SS | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% |
| Hansoh Pharma 3692.HK | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% |
| Betta Pharmaceuticals 300558.SZ | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 18.3× | 14.5% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| HUTCHMED (China) 0013.HK | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688192.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.1% | +6.9% | 4th highest of 21 |
| 6-month return | +18.4% | +9.2% | 8th highest of 21 |
| Distance from 52-week high | -5.8% | -13.1% | 6th highest of 21 |
| Revenue growth (TTM) | +720.1% | +6.3% | highest of 21 |
| Operating margin | 69.0% | 11.0% | highest of 21 |
| Forward P/E | 9.5× | 14.7× | 4th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -8.4% | 2.9% | 4th least demanding of 18 |
| Growth delivered (Del g) | +95.9% | +11.3% | highest of 18 |
| Hurdle (Req g minus delivered) | -104.2 pp | -7.2 pp | least demanding of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dizal Pharmaceutical 688192.SS | China | $4.68B | +18% | +720% | 69% | 9.5× | -8.4% | +95.9% |
| Teleperformance TEP.PA | France | $4.60B | +3% | -3% | 10% | 5.0× | -10.2% | +12.2% |
| L&T Technology Services LTTS.NS | India | $4.79B | +13% | +2% | 15% | 29.4× | 31.0% | +15.1% |
| Brink's BCO | United States | $4.54B | +3% | +7% | 10% | 11.8× | 0.1% | +7.3% |
| Aalberts AALB.AS | Netherlands | $4.87B | +6% | 0% | 10% | 14.6× | 12.9% | +3.4% |
| East Buy 1797.HK | Hong Kong | $4.11B | +22% | +34% | 11% | 38.5× | 18.4% | +54.3% |
| FTI Consulting FCN | United States | $5.33B | +19% | +8% | 10% | 18.7× | -3.6% | +9.0% |
| SAI Life Sciences SAILIFE.NS | India | $4.02B | +64% | +27% | 21% | 89.2× | n/a | n/a |
| Reply REY.MI | Italy | $5.46B | +41% | +6% | 13% | 17.0× | 2.9% | +14.4% |
| PhysicsWallah PWL.NS | India | $4.00B | +18% | +35% | 1% | 100.9× | n/a | n/a |
| Centre Testing International 300012.SZ | China | $3.96B | -5% | +15% | 16% | 22.1× | 14.2% | +13.2% |
| Alsok 2331.T | Japan | $3.79B | -1% | +7% | 8% | 13.7× | -6.0% | +4.9% |
| Beijing Compass Technology Development 300803.SZ | China | $5.91B | -23% | +12% | 0% | 174.6× | 46.9% | +25.3% |
| Nexi NEXI.MI | Italy | $5.93B | +18% | +1% | 13% | 7.0× | 1.5% | +30.5% |
| GEO GEO | United States | $3.66B | +28% | +15% | 12% | 13.5× | 6.8% | +2.3% |
| Serco SRP.L | United Kingdom | $3.60B | +5% | +1% | 5% | 14.9× | 1.9% | +4.9% |
| MITIE MTO.L | United Kingdom | $3.56B | +23% | +11% | 3% | 14.2× | 14.1% | +17.6% |
| Loomis LOOMIS.ST | Sweden | $3.46B | +12% | +1% | 11% | 12.6× | -9.1% | +9.7% |
| MAXIMUS MMS | United States | $3.43B | +2% | -3% | 11% | 7.9× | -8.5% | +9.4% |
| Elis ELIS.PA | France | $6.44B | -12% | +5% | 13% | 12.0× | 10.1% | +11.3% |
| Shenzhen Fortune Trend Technology 688318.SS | China | $3.36B | -21% | -3% | 56% | 69.5× | n/a | n/a |